Skip to main content
. 2019 Apr 29;145(10):2740–2753. doi: 10.1002/ijc.32336

Figure 5.

Figure 5

FGFR1 correlates with Crb3a in colon cancer cells. (a, d) Knockdown of FGFR1 or FGFR4 using siRNAs in (a) DLD‐1 or (d) WiDr cells were validated by immunoblot. (b, e) MTT assay using siFGFR treated (b) DLD‐1 or (e) WiDr cells. (c) Cell migration of siFGFR1 treated DLD‐1 cells was examined by transwell chamber assay. (f) Expression of FLAG‐Crb3a, FGFR1‐HIS, FGFR1Δcyto‐HIS and Tubulin in stably expressing cells was validated by immunoblot. (g) Cell migration of Crb3‐KO DLD‐1 cell stably expressing Crb3 and/or FGFR1 constructions was evaluated by transwell chamber assay. (h) Cell migration of Crb3a‐revertant DLD‐1 cells was examined by transwell chamber assay in the presence of 20 μM MEK inhibitors (SL327 or U0126). (i) ERK phosphorylation by recombinant FGF1 treatment decreased in Crb3‐KO DLD‐1 cells, and forced expression of Crb3a in Crb3‐KO cell recovered ERK phosphorylation.